Advertisement

Topics

Quentis Therapeutics Company Profile

06:19 EDT 25th June 2018 | BioPortfolio

Quentis Therapeutics is a preclinical stage biotechnology company that is translating novel biology into new therapeutic approaches to help more cancer patients benefit from immunotherapy. Based on our deep expertise in endoplasmic reticulum (ER) stress biology and the tumor microenvironment, we are pioneering first-in-class ER stress response modulators to boost the immune system’s ability to fight cancer. Our lead program is a first-in-class IRE1α inhibitor. We are pursuing multiple additional ER stress pathway targets in the tumor micro-environment, as well as in other diseases where ER stress plays an important role. Privately held, Quentis is headquartered in New York City. To learn more, please visit www.quentistx.com and follow us on Twitter at @QuentisTx.


News Articles [787 Associated News Articles listed on BioPortfolio]

Quentis Therapeutics Appoints Magram Chief Scientific Officer

Jeanne Magram has been appointed chief scientific officer of cancer immunotherapy developer Quentis Therapeutics. Before joining New York-based Quentis, Magram was chief scientific officer of Northern...

Quentis Therapeutics raises $48mm through Series A round

Cancer immunotherapy developer Quentis Therapeutics Inc. raised $48mm through its Series A round from co-lead investors Versant Ventures, Polaris Ventures, and LS Polaris Innovation Fund, along with a...

Quentis Nets $48M For Cancer Drugs, Building Buzz For NY Bio Startups

After a string of announcements a few years back, there’s been few new, high-profile biotech startups taking shape in New York. But that quiet period might be coming to an end this morning with the ...

New York Firm Raises $48 Million To Develop New Cancer Immunotherapies

Quentis Therapeutics says it has raised $48 million from venture capitalists to develop drugs that unleash the immune system against cancer.

Quentis debuts with $48M series A

Stressing out cancer

Quentis’ $48 million debut uses the Glimcher lab findings on ER stress response to simultaneously kill tumor cells and boost antitumor immunity.

Quentis Therapeutics Announces the Appointment of Jeanne Magram, Ph.D. as Chief Scientific Officer

Quentis Therapeutics Inc., a biotechnology company pursuing first-in-class endoplasmic reticulum (ER) stress response-targeted therapies to address serious diseases such as cancer...

Quentis Therapeutics Debuts with $48 Million Series A Financing to Advance First-in-Class Immunotherapies Targeting Endoplasmic Reticulum Stress Response Pathways

--Versant-seeded company focused on applying novel biology to boost anti-tumor immunity-- --Foundational science stems from landmark ER stress biology research at ...

PubMed Articles [432 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Introduction to Volume 1 of JOPT Special Issue.

Clinical Trials [144 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1237 Associated Companies listed on BioPortfolio]

Quentis Therapeutics

Quentis Therapeutics is a preclinical stage biotechnology company that is translating novel biology into new therapeutic approaches to help more cancer patients benefit from immun...

Quentis Therapeutics Inc.

Quentis Therapeutics is a preclinical stage biotechnology company that is pursuing first-in-class endoplasmic reticulum (ER) stress response-targeted therapies to address serious ...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Quentis Therapeutics" on BioPortfolio

We have published hundreds of Quentis Therapeutics news stories on BioPortfolio along with dozens of Quentis Therapeutics Clinical Trials and PubMed Articles about Quentis Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Quentis Therapeutics Companies in our database. You can also find out about relevant Quentis Therapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...


Corporate Database Quicklinks



Searches Linking to this Company Record